Uterine corpus rhabdomyosarcoma

Summary

Uterine corpus rhabdomyosarcoma (MONDO:0016260) is a disease. A subtype of mixed endometrial stromal and smooth muscle tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine corpus rhabdomyosarcoma
Mondo ID	MONDO:0016260
Orphanet	213615
NCIT	C127058
UMLS	C4288047
MedGen	925579
GARD	0020475
Anatomy (UBERON)	UBERON:0009853
Is cancer (heuristic)	no

Also known as: body of uterus rhabdomyosarcoma · body of uterus rhabdomyosarcoma (disease) · rhabdomyosarcoma (disease) of body of uterus · uterine corpus rhabdomyosarcoma

Disease family

This is a subtype of mixed endometrial stromal and smooth muscle tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › connective and soft tissue neoplasm › soft tissue neoplasm › mixed endometrial stromal and smooth muscle tumor › uterine corpus rhabdomyosarcoma

Related subtypes (3): endometrial stromal nodule, uterine corpus perivascular epithelioid cell tumor, leiomyosarcoma of the corpus uteri

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.